Le medicament du mois. Glucovance dans le diabete de type 2, une association fixe metformine-glibenclamide pour faciliter le traitement d'une maladie bipolaire.

Scheen, André

Article (Scientific journals)

Scheen, André

2003 • In Revue Médicale de Liège, 58 (6), p. 448-52

Peer reviewed

Permalink
https://hdl.handle.net/2268/10311

PubMed
12945247

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

200306_16.pdf

Publisher postprint (454.06 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2/complications/drug therapy; Glyburide/administration & dosage/pharmacology; Humans; Hypoglycemic Agents/administration & dosage/pharmacology; Insulin Resistance; Metformin/administration & dosage/pharmacology; Patient Compliance; Periodicity

Abstract :

[en] Glucovance, recently launched by Merck-Lipha (Glucovance 500 mg/2.5 mg and Glucovance 500 mg/5 mg), is a fixed combined therapy of a sulphonylurea (glibenclamide 2.5 or 5 mg) and a biguanide (metformin 500 mg), indicated for the treatment of type 2 diabetes in adult patients. The only current official indication in Belgium is the substitution of a dual therapy with metformin and glibenclamide in patients with a stable and adequate metabolic control. The fixed combination aims at simplifying patient's treatment in order to improve compliance despite polymedication. In addition, it allows targeting synergistically the two main abnormalities of type 2 diabetes, i.e. the insulin secretory defect and the insulin resistance.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Le medicament du mois. Glucovance dans le diabete de type 2, une association fixe metformine-glibenclamide pour faciliter le traitement d'une maladie bipolaire.

Alternative titles :

[en] Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease

Publication date :

2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

448-52

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 07 April 2009

Statistics

Number of views

364 (0 by ULiège)

Number of downloads

367 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen AJ, Paquot N, Lefèbvre PJ. - Etiologie et physiopathologie du diabète de type 2. Encyclopédie Médico-Chirurgicale (Paris-France). Endocrinologie-Nutrition, 1995, 10-366-D-10, 7p.
Scheen AJ. - L'"épidémie" des maladies métaboliques, un problème majeur de santé publique. Rev Med Liège, 1999, 54, 87-94.
Scheen AJ, Lefèbvre PJ. - Le diabète non insulinodépendant: de la physiopathologie au traitement. Bull Mem Acad Roy Med Belg, 1996, 151, 395-405.
Scheen AJ, Lefèbvre PJ. - Insulin resistance vs. insulin deficiency: which comes first? The old question revisited. In Diabetes in the New Millennium. Eds Di Mario U., Leonetti F., Pugliese G., Sbraccia P. and Signore A., J. Wiley & Sons, New York, 2000, 101-113.
Turner RC, Cull CA, Frighi V, Holman RR. - Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 1999, 281, 2005-2012.
Scheen AJ, Paquot N. - Le diabète de type 2: approches diagnostiques, objectifs glycémiques et stratégies thérapeutiques. Rev Med Liège, 1999, 54, 659-666.
Scheen AJ, Estrella F. - L'étude Steno-2: plaidoyer pour une prise en charge globale et intensive du patient diabétique de type 2. Rev Med Liège, 2003, 58, 109-111.
Scheen AJ. - Current management of coexisting obesity and type 2 diabetes. Drugs, 2003, 63, 1165-1184.
Scheen AJ, Lefèbvre PJ. - Oral antidiabetic agents. A guide to selection. Drugs, 1998, 55, 225-236.
European Diabetes Policy Group. - A desktop guide to Type 2 diabetes mellitus. Diabet Med, 1999, 16, 716-730.
Scheen AJ, Lefèbvre PJ. - Treatment of diabetes mellitus. In: Clinical Pharmacology, (Ed: C. Sirtori), Mc Graw Hill, London, 2000, 685-698.
Luyckx A, Daubresse JC, Carpentier JL, Lefèbvre P. - La place des biguanides dans le traitement du diabète sucré. In: Journées Annuelles de Diabétologie de l'Hôtel-Dieu, Flammarion Médecine-Sciences, Paris, 1974, 35-52.
Cusi K, DeFronzo RA. - Metformin: a review of its metabolic effects. Diabetes Rev, 1998, 6, 89-131.
DeFronzo RA. - Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med, 1999, 131, 281-303.
Howlett H, Porte F, Allavoine T, et al. - The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin, 2003, 19, 218-225.
Scheen AJ. - La non-observance thérapeutique: problème majeur pour la prévention des maladies cardiovasculaires. Rev Med Liège, 1999, 54, 914-920.
Paes AHP, Bakker A, Soe-Agbie CJ. - Impact of dose frequency on patient compliance. Diabetes Care, 1997, 20, 1512-1517.
Marathe PH, Arnold ME, Meeker J, et al. - Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol, 2000, 40, 1494-1502.
Scheen AJ, Letiexhe MR, Lefèbvre PJ. - Short administration of metformin improves insulin sensitivity in obese android subjects with impaired glucose tolerance. Diabetic Med, 1995, 12, 985-989.
Scheen AJ. - Clinical pharmacokinetics of metformin. Clin Pharmacokin, 1996, 30, 359-371.
Scheen AJ. - Pièges et conseils à propos de l'utilisation des antidiabétiques oraux conventionnels. Rev Med Liège, 2002, 57, 352-356.
Scheen AJ. - Les sulfamidés hypoglycémiants, 50 ans après Loubatières. Rev Med Liège, 1996, 51, 90-93.
Scheen A, Jaminet C, Luyckx A, Lefèbvre P. - Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420 in non insulin-dependent (type 2) diabetes. Int J Clin Pharmacol, 1987, 25, 70-76.
Scheen A, Luyckx A, Castillo M, Lefèbvre P. - Rôle thérapeutique des effets extra-pancréatiques des sulfamidés hypoglycémiants. Med Hyg, 1985, 43, 3816-3820.
Hermann LS, Schersten B, Melander A. - Antihyperglycaemic efficacy, response prediction and dose-relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med, 1994, 11, 953-960.
Marre M, Howlett H, Lehert P, Allavoine T. - Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in type 2 diabetic patients inadequately controlled with metformin. Diabetic Med, 2002, 19, 673-680.
Blonde L, Rosenstock J, Mooradian AD, et al. - Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulfonylurea therapy. Diab Obes Metab, 2002, 4, 368-375.
Garber AJ, Bruce S, Fiedorek FT. - Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. Clin Ther, 2002, 24, 1401-1413.
Garber A, Marre M, Blonde L, et al. - Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance®) in type 2 diabetes. Diab Obes Metab, 2003, 5, 171-179.
Garber AJ, Larsen J, Schneider SH, et al. - Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diab Obes Metab, 2002, 4, 201-208.
Dailey G, Kim MS, Lian JF. - Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic paients. J Int Med Res, 2002, 30, 71-79.
Melikian C, White TJ, Vanderplas A, et al. - Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Clin Ther, 2002, 24, 460-467.
Scheen AJ, Bruwier G, Schmitt H, au nom des membres de l'étude clinique DREAM. - Optimalisation de la prise en charge du patient diabétique de type 2: résultats de l'étude "DREAM" en médecine générale. Rev Med Liège, 2003, 58, 139-146.